FIELD: medicine.
SUBSTANCE: present invention describes a compound of formula I or a pharmaceutically acceptable salt or stereoisomer thereof, where R1-R5 are defined in the formula which is a JAK inhibitor. Also described is a pharmaceutical composition, a method for the treatment and the use for preparing a drug.
.
EFFECT: drug can be used for treating a disease or disorder that can be alleviated by inhibiting Janus kinases JAK1 and JAK2 in a mammal, where the condition is selected from asthma and obstructive airways diseases, autoimmune diseases or disorders and cancer, by administering to a mammal in need a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt or stereoisomer thereof.
15 cl, 33 tbl, 24 ex
| Title | Year | Author | Number |
|---|---|---|---|
| N-(2-CYANO HETEROCYCLYL)PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | 2014 |
|
RU2669922C2 |
| CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | 2014 |
|
RU2655380C2 |
| NOVEL IMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY, AND USE THEREOF | 2017 |
|
RU2702749C1 |
| HETEROARYL COMPOUNDS, COMPOSITIONS CONTAINING THEM AND METHODS OF TREATING WITH USE OF SUCH COMPOUNDS | 2007 |
|
RU2478635C2 |
| PYRAZOLO [3,4-C] PYRIDINES AND METHODS OF APPLICATION THEREOF | 2012 |
|
RU2638116C2 |
| AMINOTRIAZOLOPYRIDINES AND USING THEM AS KINASE INHIBITORS | 2009 |
|
RU2552642C2 |
| N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | 2010 |
|
RU2553681C2 |
| PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | 2013 |
|
RU2658006C2 |
| BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
| METHODS OF OBTAINING AND PURIFICATION OF HETEROARYL COMPOUNDS | 2010 |
|
RU2557242C2 |
